Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.

Gynecologic oncology - 1 Nov 2021

Contos G, Baca Y, Xiu J, Brown J, Holloway R, Korn W M, Herzog T J, Jones N, Winer I

Abstract excerpt

OBJECTIVE: Immuno-oncology (IO) has rapidly evolved, with many IO therapies either approved or under investigation for multiple malignancies. Biomarkers exist that can predict response to IO therapies including PD-L1 expression, microsatellite instability (MSI), and total mutation burden (TMB). This paper serves to analyze the presence of these biomarkers across gynecologic cancers. METHODS: A total of 16,300...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genital Neoplasms, Female

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Patient Selection

Source

Identifiers

PMID: 34563366
DOI: 10.1016/j.ygyno.2021.09.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.PMID 34563366Read ↗

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.Semantic proximity Read ↗

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.Semantic proximity Read ↗

Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.Semantic proximity Read ↗

Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.Semantic proximity Read ↗

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancerSemantic proximity Read ↗

Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.Semantic proximity Read ↗

Prevalence and molecular features of TMB-high and MSI-high breast cancer assessed by gene panel testingSemantic proximity Read ↗

A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.Semantic proximity Read ↗

Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.Semantic proximity Read ↗

Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development.Semantic proximity Read ↗

Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labsSemantic proximity Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.